Research programme: anthrax vaccine - Altimmune

Drug Profile

Research programme: anthrax vaccine - Altimmune

Alternative Names: AdVAV; NasoShield

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class Vaccines
  • Mechanism of Action Anthrax toxin modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Anthrax

Most Recent Events

  • 11 Dec 2017 Altimmune files an IND application with the US FDA in USA for Anthrax
  • 09 Nov 2017 Altimmune plans a BARDA-funded phase I trial for Anthrax in USA in the first quarter of 2018 (Intranasal) (NCT03352466)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top